VERA | Vera Therapeutics, Inc.
| Atacicept Patients with IgAN | Phase 3 | 10/17/2025 9:12 AM | Data | | |
| | OST-HER2 In patients with HER2-expressing solid tumors in breast cancer and other cancers | Type C Meeting | 10/17/2025 9:15 AM | FDA Approval | | |
VRTX | Vertex Pharmaceuticals Inc
| povetacicept in IgA nephropathy | — | 10/17/2025 9:04 AM | Provided Update | | |
| | DISC-0974 For the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease | — | 10/17/2025 9:00 AM | Data Presentation | | |
NVSNVSEF | Novartis AG
| Kisqali® (ribociclib) For breast cancer | — | 10/17/2025 8:33 AM | Results | | |
NBIX | Neurocrine Biosciences Inc
| INGREZZA (Valbenazine) Tardive Dyskinesia | — | 10/17/2025 8:30 AM | Presentation | | |
PHGEPHGE.U | BiomX Inc
| BX004 Cystic Fibrosis | — | 10/17/2025 8:30 AM | Provided Update | | |
SNSE | Sensei Biotherapeutics
| Solnerstotug in PD-(L)1 Resistant Tumors | Phase 1/2 | 10/17/2025 8:16 AM | Results | | |
| | EVX-01 Metastatic Melanoma | — | 10/17/2025 8:15 AM | Efficacy Data | | |
AGIO | Agios Pharmaceuticals Inc
| Mitapivat Sickle cell disease | European Medicines Agency (EMA) | 10/17/2025 8:15 AM | Positive Opinion | | |
| | IMNN-101 SARS CoV-2 | — | 10/17/2025 8:10 AM | Oral presentation | | |
AGEN | Agenus Inc
| Botensilimab + balstilimab Metastatic heavily pretreated microsatellite stable colorectal cancer | — | 10/17/2025 8:10 AM | New Data | | |
LLY | Eli Lilly and Co
| Verzenio plus endocrine therapy in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high-risk early breast cancer. | Phase 3 | 10/17/2025 8:05 AM | Analysis | | |
AZNAZNCF | AstraZeneca PLC
| Durvalumab Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy | Phase 3 | 10/17/2025 8:00 AM | Positive Results | | |
KNSA | Kiniksa Pharmaceuticals Ltd
| KPL-387 In recurrent pericarditis | Orphan Drug Designation | 10/17/2025 8:00 AM | Designation Grant | | |
SNSE | Sensei Biotherapeutics
| SNS-101 Suppressor of T cells by binding the receptor PSGL-1 | Phase 1/2 | 10/17/2025 8:00 AM | Results | | |
VOR | Vor Biopharma
| telitacicept Sjögren's Disease | Phase 3 | 10/17/2025 8:00 AM | Clinical Data | | |
REGNSNYSNYNF | Regeneron Pharmaceuticals Inc Sanofi SA
| Libtayo (cemiplimab) Advanced Cervical Cancer | — | 10/17/2025 7:30 AM | Positive Opinion | | |
ACHV | Achieve Life Sciences Inc
| cytisinicline For the treatment of nicotine dependence | — | 10/17/2025 7:30 AM | Provided Update | | |
INSM | Insmed Inc
| Brensocatib In Patients with Bronchiectasis | European Medicines Agency (EMA) | 10/17/2025 7:00 AM | Positive Opinion | | |
SMMT | Summit Therapeutics Inc
| Ivonescimab For Lung cancer | Phase 3 | 10/17/2025 7:00 AM | Expansion | | |
PFE | Pfizer Inc
| Dovato For adolescents living with HIV | — | 10/17/2025 7:00 AM | Findings Update | | |
| | tegoprubart For Type 1 Diabetes | — | 10/17/2025 7:00 AM | Oral presentation | | |
TNXP | Tonix Pharmaceuticals Holding Corp
| TNX-801 Potential Vaccine to Prevent Mpox and Smallpox | — | 10/17/2025 7:00 AM | Oral presentation | | |
CLYM | Climb Bio Inc
| CLYM116 for IgAN | — | 10/17/2025 7:00 AM | Upcoming presentations | | |
PLX | Protalix BioTherapeutics Inc
| ProCellEx Plant cell based protein expression system | European Medicines Agency (EMA) | 10/17/2025 6:58 AM | Negative opinion | | |
QDEL | QuidelOrtho Corporation
| ORTHO VISION for patients who depend on timely transfusion decisions. | — | 10/16/2025 8:30 PM | Highlights | | |
| | bitopertin In patients with erythropoietic protoporphyria (EPP) | — | 10/16/2025 5:39 PM | Provided Update | | |
ATAI | atai Life Sciences N.V.
| BPL-003 In Patients With Treatment Resistant Depression | Breakthrough Therapy Designation | 10/16/2025 4:10 PM | Designation Grant | | |
ABUS | Arbutus Biopharma Corp
| AB-101 Oral PD-L1 inhibitor | Fast Track Designation | 10/16/2025 4:08 PM | Designation Grant | | |
TSHA | Taysha Gene Therapies Inc
| TSHA-102 Rett Syndrome | — | 10/16/2025 4:06 PM | clinical program | | |
NVSNVSEF | Novartis AG
| iptacopan To treat adults with paroxysmal nocturnal hemoglobinuria (PNH). | Phase 3 | 10/16/2025 10:50 AM | Results | | |
PSNLAZNAZNCF | Personalis Inc AstraZeneca PLC
| NeXT Personal in patients with unresectable stage III, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). | — | 10/16/2025 9:08 AM | New Data | | |
SCNX | SCIENTURE HOLDINGS Inc
| Arbli for hypertension | — | 10/16/2025 9:00 AM | Provided Update | | |
ENTX | Entera Bio Ltd
| EB613 Parathyroid hormone (1-34), or PTH for osteoporosis | Phase 2 | 10/16/2025 8:45 AM | Clinical Data | | |
OMER | Omeros Corp
| Narsoplimab Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) | — | 10/16/2025 8:30 AM | Publication | | |
MBOT | Microbot Medical Inc
| LIBERTY® Robotic Surgical System Device | — | 10/16/2025 8:30 AM | Provided Update | | |
ALGS | Aligos Therapeutics Inc
| ALG-000184 Hepatitis B | — | 10/16/2025 8:30 AM | Provided Update | | |
NXTC | NextCure Inc
| SIM0505 in patients with advanced solid tumors. | — | 10/16/2025 8:09 AM | Dose Update | | |
JNJ | Johnson & Johnson
| TECVAYLI For patients with newly diagnosed multiple myeloma | Phase 3 | 10/16/2025 8:00 AM | Top-line results | | |
ESPR | Esperion Therapeutics Inc
| ESP-2001 Treatment of Primary Sclerosing Cholangitis | — | 10/16/2025 8:00 AM | Provided Update | | |
VOR | Vor Biopharma
| telitacicept Sjögren's Disease | Phase 3 | 10/16/2025 8:00 AM | Results | | |
NVCT | Nuvectis Pharma, Inc.
| NXP900 Novel inhibitor of the SRC family of kinases | — | 10/16/2025 8:00 AM | Upcoming presentations | | |
INSM | Insmed Inc
| Brensocatib In Patients with Bronchiectasis | Phase 3 | 10/16/2025 7:00 AM | Abstract | | |
ACET | Adicet Bio Inc
| ADI-001 B cell non-Hodgkin's lymphoma (NHL) | Phase 1 | 10/16/2025 7:00 AM | Dose Update | | |
XELAXELAU | Exela Technologies Inc
| Ulixacaltamide Designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity. | Phase 3 | 10/16/2025 7:00 AM | Positive Results | | |
| | DNTH212 BDCA2 and BAFF/APRIL inhibitor. | — | 10/16/2025 7:00 AM | Provided Update | | |
CLLSCMVLF | Cellectis SA
| UCART22 For patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia | — | 10/16/2025 7:00 AM | Provided Update | | |
MRK | Merck & Co Inc
| KEYNOTE-B96 In Patients With Platinum-Resistant Recurrent Ovarian Cancer | Phase 3 | 10/16/2025 6:45 AM | Secondary Endpoint | | |
MIRA | MIRA PHARMACEUTICALS, INC.
| MIRA-55 Potential treatment for anxiety and cognitive decline. | — | 10/15/2025 4:06 PM | New Data | | |
SONN | Sonnet BioTherapeutics Holdings Inc
| SON-1010 Advanced Solid Tumors | — | 10/15/2025 10:03 AM | Provided Update | | |
| | DurAVR® Transcatheter Heart Valve in patients with severe calcific aortic stenosis | — | 10/15/2025 9:18 AM | Regulatory Update | | |
ARTL | Artelo Biosciences Inc
| ART26.12 For the prevention of chemotherapy-induced peripheral neuropathy, a debilitating and often treatment-altering side effect of cancer therapy. | — | 10/15/2025 9:18 AM | Data Presentation | | |
NNVC | Nanoviricides Inc
| NV-387 For MPox and Smallpox virus infections | — | 10/15/2025 8:45 AM | Publication | | |
BLTE | Belite Bio, Inc.
| Tinlarebant In Stargardt Disease | New Drug Application (NDA) | 10/15/2025 8:00 AM | Regulatory Update | | |
| | ABS-201 for androgenetic alopecia | — | 10/15/2025 8:00 AM | Provided Update | | |
MNPR | Monopar Therapeutics Inc
| ALXN1840-WD-204 Liver Diseases | Phase 2 | 10/15/2025 8:00 AM | Abstract | | |
APRE | Aprea Therapeutics Inc
| ATRN-119 in patients with advanced solid tumors. | Phase 2 | 10/15/2025 8:00 AM | Dosing Update | | |
STXS | Stereotaxis Inc
| Synchrony™ system. for Synchrony Surgical Robotics System | European Union CE Mark | 10/15/2025 7:35 AM | Regulatory Update | | |
| | tafenoquine For treatment of babesiosis | — | 10/15/2025 7:16 AM | Provided Update | | |
NVCR | NovoCure Ltd
| gemcitabine and nab-paclitaxel (GnP) first-line treatment for adults with unresectable, locally advanced pancreatic adenocarcinoma, compared to GnP alone. | — | 10/15/2025 7:00 AM | Data Presentation | | |
GYRE | Gyre Therapeutics
| pirfenidone In Oncology-Related Pulmonary Complications | Phase 3 | 10/15/2025 7:00 AM | Enrollment Update | | |
LLY | Eli Lilly and Co
| orforglipron Orforglipron for the treatment of obesity and overweight | Phase 3 | 10/15/2025 6:45 AM | Top-line results | | |
MRK | Merck & Co Inc
| Doravirine/Islatravir In adults with HIV-1 infection | Phase 3 | 10/15/2025 6:45 AM | Additional data | | |
AUPAUPH | Aurinia Pharmaceuticals Inc
| LUPKYNIS (voclosporin) Lupus Nephritis | — | 10/15/2025 6:02 AM | Poster Presentation | | |
ARGNFARGX | argenx SE
| VYVGART (efgartigimod alfa) For Adults with Primary Immune Thrombocytopenia | — | 10/15/2025 1:00 AM | Data Presentation | | |
ACOGF | Alpha Cognition Inc.
| ALPHA-1062 Mild to Moderate Alzheimer's Disease | — | 10/14/2025 4:30 PM | Clinical Update | | |
XNCR | Xencor Inc
| XmAb819 patients with clear cell renal cell carcinoma | — | 10/14/2025 12:45 PM | Upcoming presentations | | |
| | IGC-AD1 For Agitation in Alzheimer's disease. | Phase 2 | 10/14/2025 9:00 AM | Expansion | | |
CELU | Celularity Inc.
| PDA-002 For treating Facioscapulohumeral Muscular Dystrophy (FSHD). | Phase 2 | 10/14/2025 8:45 AM | Publication | | |
CLRB | Cellectar Biosciences Inc
| CLR 121225 For pancreatic cancer | — | 10/14/2025 8:30 AM | Preclinical Data | | |
| | IMNN-001 For ovarian cancer | Phase 3 | 10/14/2025 8:20 AM | Abstract | | |
VOR | Vor Biopharma
| telitacicept Sjögren's Disease | — | 10/14/2025 8:12 AM | Positive Results | | |
KRYS | Krystal Biotech Inc
| KB801 For the Treatment of Neurotrophic Keratitis | Platform technology designation | 10/14/2025 8:09 AM | Designation Grant | | |
NCNA | NuCana PLC
| NuTide:303 In medRxiv And PLOS ONE | — | 10/14/2025 8:07 AM | Data Publication | | |
| | TTX-MC138 metastatic disease | Phase 1a | 10/14/2025 8:06 AM | Clinical Trial | | |
| | Telomir-1 Potential treatment for age-related conditions | — | 10/14/2025 8:00 AM | Findings Update | | |
CADL | Candel Therapeutics, Inc.
| CAN-3110 Recurrent high-grade Glioma | — | 10/14/2025 8:05 AM | Interim Data | | |
CRBP | Corbus Pharmaceuticals Holdings Inc
| CRB-701 Targets the expression of Nectin-4 on cancer cells | Phase 1/2 | 10/14/2025 8:00 AM | Abstract | | |
SPRO | Spero Therapeutics Inc
| Tebipenem Adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) | — | 10/14/2025 8:00 AM | Presentation | | |
APRE | Aprea Therapeutics Inc
| APR-1051 Next Generation WEE1 Kinase Inhibitor | — | 10/14/2025 8:00 AM | Abstract | | |
LXRX | Lexicon Pharmaceuticals Inc
| pilavapadin For the treatment of diabetic peripheral neuropathic pain (DPNP) | — | 10/14/2025 8:00 AM | Additional data | | |
CING | Cingulate Inc.
| CTx-1301 Attention Deficit/Hyperactivity Disorder (ADHD) | New Drug Application (NDA) | 10/14/2025 8:00 AM | review | | |
SNGX | Soligenix Inc
| HyBryte In the treatment of cutaneous T-cell lymphoma (CTCL) | Phase 3 | 10/14/2025 7:33 AM | Guidance | | |
MRUS | Merus NV
| petosemtamab For the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) | — | 10/14/2025 7:30 AM | Interim Data | | |
NEO | NeoGenomics Inc
| RaDaR ST sequencing data from tumor samples and advanced bioinformatics to create patient-specific MRD panels. | — | 10/14/2025 7:05 AM | Presentation Update | | |
TNXP | Tonix Pharmaceuticals Holding Corp
| TNX-1500 Humanized monoclonal antibody | — | 10/14/2025 7:19 AM | Provided Update | | |
ARMP | Armata Pharmaceuticals Inc
| AP-SA02 For complicated Staphylococcus aureus bacteremia. | Phase 2a | 10/14/2025 7:00 AM | Late-Breaking Data | | |
DTIL | Precision BioSciences Inc
| ARCUS Eliminate DNA of living cells and organisms. | — | 10/14/2025 7:01 AM | Oral presentation | | |
IMAB | I-MAB
| Givastomig In patients with advanced cancers | Phase 1 | 10/14/2025 7:00 AM | Abstract | | |
TRAW | Traws Pharma Inc
| ratutrelvir An Oral Mpro Inhibitor | Phase 2 | 10/14/2025 7:00 AM | Dosing Update | | |
RCKT | Rocket Pharmaceuticals Inc
| KRESLADI For severe Leukocyte Adhesion Deficiency-I | — | 10/14/2025 7:00 AM | BLA Resubmission | | |
MCRB | Seres Therapeutics Inc
| SER-155 Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD) | Phase 1b | 10/14/2025 7:00 AM | Data | | |
TNXP | Tonix Pharmaceuticals Holding Corp
| TNX-1500 Humanized monoclonal antibody | — | 10/14/2025 7:00 AM | Provided Update | | |
FULC | Fulcrum Therapeutics Inc
| FTX-6274 EED, inhibitor, in castration-resistant prostate cancer. | — | 10/14/2025 7:00 AM | Preclinical Data | | |
GYRE | Gyre Therapeutics
| Hydronidone Treatment of Liver Fibrosis in Chronic Hepatitis B | Phase 3 | 10/14/2025 7:00 AM | Results | | |
BTAI | BioXcel Therapeutics Inc
| BXCL501 (SERENITY) Schizophrenia and bipolar disorders | — | 10/14/2025 7:00 AM | Positive Results | | |
SGENPFE | Seagen Inc Pfizer Inc
| TUKYSA (Tucatinib) Metastatic HER2-Positive Breast Cancer | Phase 3 | 10/14/2025 6:45 AM | Positive Results | | |
| | denifanstat For Liver Diseases | pre-New Drug Application (NDA) | 10/14/2025 6:00 AM | Provided Update | | |
TBPH | Theravance Biopharma Inc
| YUPELRI (Revefenacin) Chronic obstructive pulmonary disease (COPD) | — | 10/14/2025 6:00 AM | Presentation | | |
ZLAB | Zai Lab Ltd
| ZL-1310 For DLL3+ Solid Tumors | — | 10/13/2025 12:07 PM | Late-breaking abstract | | |
ATNM | Actinium Pharmaceuticals Inc
| ATNM-400 Prostate Cancer Radiotherapy | — | 10/13/2025 12:14 PM | Preclinical Data | | |
NUVL | Nuvalent, Inc.
| NVL-330 For pre-treated patients with HER2-altered non-small cell lung cancer (NSCLC). | — | 10/13/2025 12:53 PM | Upcoming presentations | | |
PMVP | PMV Pharmaceuticals Inc
| rezatapopt In patients with advanced solid tumors | — | 10/13/2025 4:01 PM | Abstract Presentation | | |
ZYME | Zymeworks Inc
| ZW191 A Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate | Phase 1 | 10/13/2025 4:02 PM | Poster Presentation | | |
DNLI | Denali Therapeutics Inc
| tividenofusp alfa Treatment For Hunter Syndrome | Biologics License Applications (BLA) | 10/13/2025 4:03 PM | Review Extension | | |
RPTX | Repare Therapeutics Inc
| RP-1664 Oral PLK4 Inhibitor | Phase 1 | 10/13/2025 4:05 PM | Top-line data | | |
| | BBI-825 In Cancer Patients with Resistance Gene Amplifications | — | 10/13/2025 4:10 PM | Upcoming presentations | | |
ANAB | AnaptysBio Inc
| Rosnilimab (formerly ANB030) Healthy Volunteer | Phase 2b | 10/13/2025 9:15 AM | Data Presentation | | |
RNA | Avidity Biosciences Inc
| del-zota for people living with Duchenne Muscular Dystrophy amenable to exon 44 skipping (DMD44). | Pre-BLA Meeting | 10/13/2025 9:00 AM | FDA Meeting | | |
PALI | Palisade Bio, Inc.
| PALI-2108 For patients affected by UC. | — | 10/13/2025 8:49 AM | Provided Update | | |
| | ProSense Cryoablation System T1 invasive breast cancer and/or patients not suitable for surgical alternatives for the treatment of breast cancer | — | 10/13/2025 8:30 AM | Provided Update | | |
ATNM | Actinium Pharmaceuticals Inc
| ATNM-400 Prostate Cancer Radiotherapy | — | 10/13/2025 8:30 AM | Preclinical Data | | |
ANGO | AngioDynamics Inc
| NanoKnife System Treating men with unifocal intermediate-risk prostate cancer | — | 10/13/2025 8:30 AM | Provided Update | | |
GILD | Gilead Sciences Inc
| Trodelvy (sacituzumab govitecan-hziy) Metastatic urothelial cancer (UC) | — | 10/13/2025 8:30 AM | Provided Update | | |
| | CER-1236 For Ovarian Cancer | Phase 1 | 10/13/2025 8:30 AM | Clinical Trial | | |
MNKD | MannKind Corp
| Afrezza (Technosphere Insulin or TI) Type 2 (T2D) diabetes | Biologics License Applications (BLA) | 10/13/2025 8:05 AM | FDA Accepted | | |
AORT | Artivion, Inc.
| AMDS Hybrid Prosthesis Acute DeBakey Type I Aortic Dissections | — | 10/13/2025 8:00 AM | Data Presentation | | |
ATOS | Atossa Therapeutics Inc
| Z-endoxifen Breast cancer in the neoadjuvant (prior to surgery) setting | — | 10/13/2025 8:00 AM | Provided Update | | |
APYX | Apyx Medical Corp
| Renuvion Contracting subcutaneous soft tissue following liposuction in multiple areas of the body | — | 10/13/2025 8:00 AM | Provided Update | | |
FDMT | 4D Molecular Therapeutics Inc
| 4D-710 Cystic fibrosis lung disease | — | 10/13/2025 8:00 AM | Provided Update | | |
| | EVX-01 Metastatic Melanoma | — | 10/13/2025 8:00 AM | Data Presentation | | |
HCM | HUTCHMED (China) Limited
| FRUSICA-2 Advanced Renal Cell Carcinoma | — | 10/13/2025 12:00 AM | Results | | |
IMMPPRRUF | Immutep Ltd
| eftilagimod alpha For cancer and autoimmune disease | — | 10/13/2025 8:00 AM | Positive Feedback | | |
CDTX | Cidara Therapeutics Inc
| CD388 Universal Prevention and Treatment of Influenza | Phase 2 | 10/13/2025 8:00 AM | Late-Breaking Data | | |
| | VCN-01 Retinoblastoma | — | 10/13/2025 8:00 AM | Upcoming presentations | | |
SLS | SELLAS Life Sciences Group Inc
| SLS009 For Treatment of Acute Myeloid Leukemia | — | 10/13/2025 8:00 AM | Presentation | | |
BCAX | Bicara Therapeutics Inc
| ficerafusp alfa squamous cancer of the anal canal (SCAC). | Breakthrough Therapy Designation | 10/13/2025 7:30 AM | Designation Grant | | |
| | QTORIN™ rapamycin In the Journal of Vascular Anomalies | — | 10/13/2025 7:30 AM | Provided Update | | |
ABEO | Abeona Therapeutics Inc
| ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) | Rare Disease Endpoint Advancement (RDEA) Pilot Program. | 10/13/2025 7:30 AM | Provided Update | | |
TVRD | Tvardi Therapeutics Inc
| TTI-101 In Idiopathic Pulmonary Fibrosis | Phase 2 | 10/13/2025 7:30 AM | Provided Update | | |
BCTBCTX | BriaCell Therapeutics Corp
| Bria-IMT Metastatic breast cancer (breast cancer that has spread beyond the breast) | Phase 3 | 10/13/2025 7:30 AM | Data Presentation | | |
ABBV | AbbVie Inc
| Temab-A Advancing Targeted Therapies for Solid Tumors | — | 10/13/2025 7:15 AM | New Data | | |
PGEN | Precigen Inc
| PAPZIMEOS For Treatment Of Adults With Recurrent Respiratory Papillomatosis | — | 10/13/2025 7:00 AM | Follow-up data | | |
CGEN | Compugen Ltd
| COM701 Solid tumors | — | 10/13/2025 7:00 AM | Analysis | | |
ARVN | Arvinas Inc
| Vepdegestrant For ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. | — | 10/13/2025 7:00 AM | New Data | | |
AZNAZNCF | AstraZeneca PLC
| Durvalumab Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy | — | 10/13/2025 7:00 AM | New Data | | |
BMYBMYMP | Bristol-Myers Squibb Company
| iza-bren For Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer | — | 10/13/2025 6:59 AM | Data Presentation | | |
LLYTNGX | Eli Lilly and Co Tango Therapeutics, Inc.
| Verzenio (abemaciclib) Hormone Receptor-Positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC) | — | 10/13/2025 6:45 AM | New Data | | |
PFE | Pfizer Inc
| ABRYSVO Vaccine indicated for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in people 60 years of age and older. | — | 10/13/2025 6:45 AM | Data Presentation | | |
ONC | BeOne Medicines Ltd
| sonrotoclax Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Breakthrough Therapy Designation | 10/13/2025 6:00 AM | Designation Grant | | |
CGEM | Cullinan Therapeutics Inc
| zipalertinib For patients with heavily pre-treated EGFR ex20ins mutation NSCLC | — | 10/12/2025 6:27 PM | New Data | | |
MRNA | Moderna Inc
| mRNA-4359 Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma | Phase 1/2 | 10/12/2025 6:05 PM | Safety Data | | |
RCUS | Arcus Biosciences Inc
| STAR-221 For Metastatic Upper GI Cancers | Phase 2 | 10/12/2025 6:05 PM | Results | | |
CRSP | CRISPR Therapeutics AG
| SyNTase Gene Editing Technology | — | 10/10/2025 8:00 AM | Preclinical Data | | |
ASMB | Assembly Biosciences Inc
| ABI-5366 For recurrent genital herpes. | Phase 1b | 10/10/2025 8:00 AM | Clinical Data | | |
CDTX | Cidara Therapeutics Inc
| CD388 Universal Prevention and Treatment of Influenza | — | 10/10/2025 8:00 AM | Late Breaking Presentation | | |
INSP | Inspire Medical Systems Inc
| Inspire V for patients with obstructive sleep apnea (OSA) | — | 10/10/2025 7:00 AM | Outcome | | |
ITCIJNJ | Intra-Cellular Therapies Inc Johnson & Johnson
| CAPLYTA (Lumateperone) Depressive Episodes associated with Bipolar | — | 10/10/2025 7:30 AM | Abstract Presentation | | |
AVXL | Anavex Life Sciences Corp
| ANAVEX®2-73-AD-EP-004 for the potential treatment of early Alzheimer's disease. | — | 10/10/2025 7:31 AM | Oral presentation | | |
PLSE | Pulse Biosciences Inc
| nPulse™ Cardiac Surgical System treatment of atrial fibrillation (AF) | — | 10/10/2025 7:00 AM | Results | | |
| | OST-HER2 In patients with HER2-expressing solid tumors in breast cancer and other cancers | Phase 2b | 10/10/2025 6:00 AM | Survival data | | |
STOK | Stoke Therapeutics Inc
| zorevunersen For the treatment of Dravet syndrome with a confirmed mutation, | — | 10/09/2025 4:30 PM | Presentation | | |
QNCX | Quince Therapeutics Inc
| eDSP For Treatment Of Rare Neurodegenerative Disease Ataxia-Telangiectasia | — | 10/09/2025 4:05 PM | Poster Presentation | | |
VIR | Vir Biotechnology Inc
| VIR-5500 Treatment of Metastatic Prostate Cancer | Phase 1 | 10/09/2025 4:05 PM | Dose Update | | |
CABA | Cabaletta Bio Inc
| CABA-201 For Treatment of Generalized Myasthenia Gravis | — | 10/09/2025 12:00 PM | Initial Data | | |
EDIT | Editas Medicine Inc
| EDIT-401 Gene and Cell Therapy | — | 10/09/2025 11:01 AM | Data | | |
ADIL | Adial Pharmaceuticals Inc
| AD04 Alcohol Use Disorder (AUD) | — | 10/09/2025 8:40 AM | Provided Update | | |
ABBV | AbbVie Inc
| BOTOX (onabotulinumtoxinA) Upper Limb Spasticity | — | 10/09/2025 8:00 AM | Provided Update | | |
ATXS | Astria Therapeutics, Inc.
| Navenibart For the Treatment of Hereditary Angioedema | — | 10/09/2025 8:00 AM | Poster Presentation | | |
| | TACTI-004 In Non-Small Cell Lung Cancer | Phase 3 | 10/09/2025 8:00 AM | Enrollment Update | | |
MIST | Milestone Pharmaceuticals Inc
| Etripamil For Treatment in Paroxysmal Supraventricular Tachycardia | — | 10/09/2025 8:00 AM | Poster Presentation | | |
OBIO | Orchestra BioMed Holdings Inc
| Atrioventricular Interval Modulation ("AVIM") Therapy in the management of hypertensive heart disease | — | 10/09/2025 8:00 AM | Data Presentation | | |
TSHA | Taysha Gene Therapies Inc
| TSHA-102 Rett Syndrome | Phase 1/2 | 10/09/2025 8:00 AM | Results | | |
CDTX | Cidara Therapeutics Inc
| CD388 Universal Prevention and Treatment of Influenza | Breakthrough Therapy Designation | 10/09/2025 8:00 AM | Designation Grant | | |
ACXP | Acurx Pharmaceuticals, Inc.
| ACX-375C DNA Polymerase IIIC Inhibitors | — | 10/09/2025 7:30 AM | Provided Update | | |
| | OST-HER2 In patients with HER2-expressing solid tumors in breast cancer and other cancers | — | 10/09/2025 7:40 AM | Regulatory Update | | |
ANVS | Annovis Bio Inc
| Buntanetap Parkinson's Disease (PD) | — | 10/09/2025 7:30 AM | Results | | |
ALRN | Aileron Therapeutics Inc
| LTI-03 In Idiopathic Pulmonary Fibrosis | European Medicines Agency (EMA) | 10/09/2025 7:30 AM | Authorization | | |
ATHEPRNAF | Alterity Therapeutics Ltd
| ATH434 To inhibit the aggregation of pathological proteins implicated in neurodegeneration | Phase 2 | 10/09/2025 7:25 AM | Data | | |
| | B-FREE for Chronic Babesiosis Treatment | — | 10/09/2025 7:18 AM | Study Initiation | | |
TNXP | Tonix Pharmaceuticals Holding Corp
| TNX-801 Potential Vaccine to Prevent Mpox and Smallpox | — | 10/09/2025 7:00 AM | Provided Update | | |
ABBVRGNX | AbbVie Inc Regenxbio Inc
| ABBV-RGX-314 In patients with wet AMD | Phase 2 | 10/09/2025 7:05 AM | Data Presentation | | |
LGND | Ligand Pharmaceuticals Inc
| Lasix® ONYU Home Treatment for Edema in Heart Failure Patients | — | 10/09/2025 7:00 AM | FDA Approval | | |
GHRS | GH Research PLC
| GH001 Resistant Depression | Phase 2b | 10/09/2025 7:00 AM | Presentation | | |
| | NGN-401 For Rett Syndrome | — | 10/09/2025 7:00 AM | Dosing Update | | |
| | NGN-401 For Rett Syndrome | — | 10/09/2025 7:00 AM | Provided Update | | |
MRK | Merck & Co Inc
| Doravirine/Islatravir In adults with HIV-1 infection | — | 10/09/2025 7:00 AM | Findings Update | | |
GANX | Gain Therapeutics, Inc.
| GT-02287 GBA1 Parkinson's disease | — | 10/09/2025 7:00 AM | Provided Update | | |
BDX | BD (Becton, Dickinson and Company)
| XTRACT™ Peripheral Artery Disease | — | 10/09/2025 6:53 AM | Enrollment Update | | |
MRK | Merck & Co Inc
| KEYTRUDA®(pembrolizumab) For the treatment of patients with locally advanced or metastatic urothelial carcinoma | — | 10/09/2025 6:45 AM | Provided Update | | |
GLSI | Greenwich LifeSciences Inc
| GLSI-100 Breast cancer recurrences | — | 10/09/2025 6:00 AM | Expansion | | |
GTBP | GT Biopharma Inc
| GTB-3650 For Treatment of CD33+ Leukemia | Phase 1 | 10/08/2025 9:00 AM | Enrollment Update | | |
REGNSNYSNYNF | Regeneron Pharmaceuticals Inc Sanofi SA
| Libtayo (Cemiplimab-Rwlc) Advanced Non-Small Cell Lung Cancer (NSCLC) with PD-L1 | — | 10/08/2025 2:31 PM | Approved | | |
RIGL | Rigel Pharmaceuticals Inc
| R289 For Lower-Risk MDS | Phase 1b | 10/08/2025 9:34 AM | Enrollment Update | | |
ATXS | Astria Therapeutics, Inc.
| Navenibart For the Treatment of Hereditary Angioedema | Phase 3 | 10/08/2025 9:33 AM | Initiation | | |
HOWL | Werewolf Therapeutics, Inc.
| WTX-124 Solid Tumors | Fast Track Designation | 10/08/2025 9:32 AM | Designation Grant | | |
AARD | Aardvark Therapeutic Inc
| ARD-101 for Prader-Willi Syndrome | — | 10/08/2025 9:30 AM | Provided Update | | |
TRVI | Trevi Therapeutics Inc
| nalbuphine ER chronic cough in patients with idiopathic pulmonary fibrosis (IPF) | — | 10/08/2025 9:29 AM | Abstract Presentation | | |
ABEO | Abeona Therapeutics Inc
| ZEVASKYN To Treat Wounds in Painful Skin Disorder | — | 10/08/2025 9:26 AM | Provided Update | | |
MDT | Medtronic PLC
| Hugo for gynecological procedures | — | 10/08/2025 7:10 AM | Clinical Study | | |
| | neflamapimod In patients with dementia with Lewy bodies (DLB) | Phase 2b | 10/08/2025 7:00 AM | Additional data | | |
AQST | Aquestive Therapeutics Inc
| Anaphylm For epinephrine prodrug candidate product | — | 10/08/2025 7:00 AM | Provided Update | | |
IMRN | Immuron Ltd
| IMM-529 Oral polyclonal antibody, targeting toxin B in the human gut and neutralises main virulence factors of Clostridium infection | Investigational New Drug (IND) | 10/08/2025 6:00 AM | IND Submission | | |
CLPT | ClearPoint Neuro Inc
| ClearPoint Prism Neuro Laser Therapy System Brain Tumor Laser Therapy | Phase 1/2 | 10/07/2025 4:15 PM | Results | | |
IMMX | Immix Biopharma, Inc.
| NXC-201 NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. | — | 10/07/2025 4:10 AM | Presentation | | |
VRCA | Verrica Pharmaceuticals Inc
| VP-315 For the Treatment of Basal Cell Carcinoma | — | 10/07/2025 4:05 PM | Presentation | | |
AZNAZNCF | AstraZeneca PLC
| Bax24 Patients with treatment-resistant hypertension (rHTN) | — | 10/07/2025 5:23 AM | Results | | |
CTXR | Citius Pharmaceuticals Inc
| LYMPHIR For the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma | — | 10/07/2025 9:17 AM | Provided Update | | |
AEMD | Aethlon Medical Inc
| Hemopurifier Severe COVID-19 | — | 10/07/2025 8:01 AM | Provided Update | | |
JNJ | Johnson & Johnson
| Icotrokinra For adults and adolescents with plaque psoriasis | Phase 2b | 10/07/2025 8:10 AM | Results | | |
JNJ | Johnson & Johnson
| Guselkumab For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis | Phase 3 | 10/07/2025 8:05 AM | New Data | | |
JNJ | Johnson & Johnson
| ACUVUE OASYS MAX 1-Day for Astigmatism | — | 10/07/2025 8:00 AM | New Data | | |
COCH | Envoy Medical® Inc
| Acclaim for Breakthrough Hearing Device | — | 10/07/2025 8:00 AM | FDA approved | | |
INVA | Innoviva Inc
| Zoliflodacin For the Treatment of Uncomplicated Gonorrhea | — | 10/07/2025 8:00 AM | Data | | |
GALT | Galectin Therapeutics Inc
| Belapectin (Formerly GR-MD-02) Non-alcoholic steatohepatitis (NASH) with cirrhosis | — | 10/07/2025 8:00 AM | Provided Update | | |
ABUS | Arbutus Biopharma Corp
| AB-101 Oral PD-L1 inhibitor | — | 10/07/2025 8:00 AM | Abstract | | |
AVIR | Atea Pharmaceuticals Inc
| Bemnifosbuvir COVID-19 | — | 10/07/2025 8:00 AM | New Data | | |
JNJ | Johnson & Johnson
| apalutamide For the treatment of prostate cancer (nmCRPC) | — | 10/07/2025 8:00 AM | Presentation | | |
KAPA | Kairos Pharma Ltd
| carotuximab in advanced, castration-resistant prostate cancer | — | 10/07/2025 8:00 AM | Presentation | | |
| | Telomir-1 Potential treatment for age-related conditions | — | 10/07/2025 7:30 AM | Results | | |
SNGX | Soligenix Inc
| HyBryte In the treatment of cutaneous T-cell lymphoma (CTCL) | — | 10/07/2025 7:30 AM | Data Safety Monitoring Board (DSMB) Meeting | | |
ARWR | Arrowhead Pharmaceuticals Inc
| ARO-DIMER-PA for the Treatment of Mixed Hyperlipidemia | — | 10/07/2025 7:30 AM | Provided Update | | |
NVAX | Novavax Inc
| Nuvaxovid Covid-19 | — | 10/07/2025 7:00 AM | Provided Update | | |
PLSE | Pulse Biosciences Inc
| nPulse™ Cardiac Surgical System treatment of atrial fibrillation (AF) | — | 10/07/2025 7:00 AM | Upcoming presentations | | |
| | denifanstat For Liver Diseases | Phase 2b | 10/07/2025 7:00 AM | Analysis | | |
| | Rejuva For the treatment of obesity and type 2 diabetes (T2D), | — | 10/07/2025 7:00 AM | Preclinical Data | | |
ENTA | Enanta Pharmaceuticals Inc
| zelicapavir For respiratory syncytial virus | — | 10/07/2025 7:05 AM | Data | | |
ENTA | Enanta Pharmaceuticals Inc
| EDP-323 Eduction in RSV replication with picomolar potency in primary human bronchial epithelial cells against RSV A and B | — | 10/07/2025 7:00 AM | Data | | |
AKRO | Akero Therapeutics Inc
| Efruxifermin Non-alcoholic steatohepatitis (NASH) | — | 10/07/2025 7:00 AM | Upcoming presentations | | |
LLY | Eli Lilly and Co
| mirikizumab-mrkz For Crohn's disease | — | 10/07/2025 6:45 AM | New Data | | |
ACET | Adicet Bio Inc
| ADI-001 B cell non-Hodgkin's lymphoma (NHL) | — | 10/07/2025 6:45 AM | Efficacy and Safety Data | | |
| | LX2006 For the Treatment of Friedreich's Ataxia Cardiomyopathy | Phase 1/2 | 10/07/2025 6:00 AM | Provided Update | | |
DYN | Dyne Therapeutics Inc
| DYNE-101 Designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus | Phase 1/2 | 10/06/2025 6:01 PM | Additional data | | |
BIIB | Biogen Inc
| LEQEMBI® (lecanemab-irmb) Treatment of Alzheimer's Disease | — | 10/06/2025 4:30 PM | Provided Update | | |
| | Telomir-1 Potential treatment for age-related conditions | — | 10/06/2025 4:06 PM | New Data | | |
BMEA | Biomea Fusion, Inc.
| icovamenib For 2 diabetes | — | 10/06/2025 4:03 PM | Results | | |
KALV | KalVista Pharmaceuticals Inc
| sebetralstat Therapy for hereditary angioedema (HAE). | — | 10/06/2025 4:00 PM | New Data | | |
NRSN | NeuroSense Therapeutics Ltd
| PrimeC Amyotrophic lateral sclerosis | — | 10/06/2025 9:07 AM | Findings Update | | |
ABBV | AbbVie Inc
| BOTOX (onabotulinumtoxinA) Upper Limb Spasticity | Phase 2 | 10/06/2025 9:00 AM | Top-line results | | |
RNA | Avidity Biosciences Inc
| EXPLORE44 in People Living with DMD44 | — | 10/06/2025 9:00 AM | Oral presentation | | |
JAGX | Jaguar Health Inc
| Crofelemer Microvillus inclusion disease (MVID) - Rare congenital diarrheal disorder | Type C Meeting | 10/06/2025 9:00 AM | Provided Update | | |
EDIT | Editas Medicine Inc
| EDIT-401 Gene and Cell Therapy | — | 10/06/2025 9:00 AM | Oral presentation | | |
ARQT | Arcutis Biotherapeutics Inc
| ZORYVE™ (roflumilast) Inhibitor of phosphodiesterase-4 (PDE4) | supplemental New Drug Application (sNDA) | 10/06/2025 8:00 AM | FDA approved | | |
ACOGF | Alpha Cognition Inc.
| ZUNVEYL For the Treatment of Mild to Moderate Alzheimer's Disease | — | 10/06/2025 8:34 AM | Presentation | | |
NBIX | Neurocrine Biosciences Inc
| INGREZZA (Valbenazine) Tardive Dyskinesia | — | 10/06/2025 8:30 AM | Data | | |
HUMA | Humacyte, Inc.
| Human Acellular Vessel Coronary Artery Bypass Grafting | — | 10/06/2025 8:00 AM | Publication | | |
PLRZ | Polyrizon Ltd
| PL-14 For seasonal allergic rhinitis. | — | 10/06/2025 8:21 AM | Results | | |
GANX | Gain Therapeutics, Inc.
| GT-02287 GBA1 Parkinson's disease | — | 10/06/2025 8:15 AM | Poster Presentation | | |
ATOS | Atossa Therapeutics Inc
| Z-endoxifen Breast cancer in the neoadjuvant (prior to surgery) setting | Phase 2 | 10/06/2025 8:00 AM | Provided Update | | |
RCUS | Arcus Biosciences Inc
| ARC-20 In patients that had received both prior TKI and anti-PD-1 therapy. | — | 10/06/2025 8:00 AM | Data | | |
| | VCN-12 to treat cancer and related diseases | — | 10/06/2025 8:00 AM | Upcoming presentations | | |
SPRB | Spruce Biosciences Inc
| TA-ERT for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). | Breakthrough Therapy Designation | 10/06/2025 8:00 AM | Designation Grant | | |
CNTX | Context Therapeutics Inc
| CT-95 For mesothelin-expressing cancers. | — | 10/06/2025 7:30 AM | Poster Presentation | | |
RGNX | Regenxbio Inc
| surabgene lomparvovec for Wet AMD | — | 10/06/2025 7:05 AM | Enrollment Update | | |
CDNA | CareDx Inc
| AlloSeq HCT Chimerism testing kit for Hematopoietic Cell Transplantation | — | 10/06/2025 7:05 AM | Provided Update | | |
XCUR | Exicure Inc
| burixafor In Multiple Myeloma | — | 10/06/2025 7:04 AM | Provided Update | | |
| | VYD2311 Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ | Investigational New Drug (IND) | 10/06/2025 7:01 AM | FDA Clearance | | |
SKYE | Skye Bioscience, Inc.
| CBeyond for obesity and other metabolic health disorders | Phase 2a | 10/06/2025 7:00 AM | Top-line data | | |
TNGX | Tango Therapeutics, Inc.
| TNG260 Immunotherapy of Cancer | — | 10/06/2025 7:00 AM | Poster Presentation | | |
CLRB | Cellectar Biosciences Inc
| Iopofosine I-131 Pediatric Brain and Solid Tumors | European Commission Conditional Marketing Authorization | 10/06/2025 7:00 AM | Marketing authorization | | |
LYRA | Lyra Therapeutics Inc
| LYR-210 Chronic Rhinosinusitis | Phase 3 | 10/06/2025 7:00 AM | Upcoming presentations | | |
MRK | Merck & Co Inc
| MK-7240 In Inflammatory Bowel Disease | Phase 2b | 10/06/2025 6:45 AM | Study Initiation | | |
CXRXF | Advanz Pharma Corp Ltd
| AVT23 a proposed biosimilar to Xolair® (omalizumab). | — | 10/06/2025 4:40 AM | Marketing authorization | | |
| | obefazimod for the treatment of moderate-to-severely active ulcerative colitis | — | 10/06/2025 4:10 AM | Additional data | | |
| | Privosegtor For Vision Loss | — | 10/06/2025 4:10 AM | Provided Update | | |
AZNAZNCF | AstraZeneca PLC
| Datopotamab deruxtecan (Dato-DXd) Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer | — | 10/06/2025 3:24 AM | Positive Results | | |
ARVN | Arvinas Inc
| ARV-102 PROTAC® degrader designed to target the LRRK2 protein | Phase 1 | 10/05/2025 2:00 PM | Positive Data | | |
| | obefazimod for the treatment of moderate-to-severely active ulcerative colitis | — | 10/05/2025 11:00 AM | Results | | |
| | SPY002 For enhanced potency to both TL1A monomers and trimers | — | 10/05/2025 9:00 AM | Presentation | | |
| | ProSense Cryoablation System T1 invasive breast cancer and/or patients not suitable for surgical alternatives for the treatment of breast cancer | — | 10/03/2025 12:22 PM | Marketing authorization | | |
OVID | Ovid Therapeutics Inc
| OV329 In Treatment-Resistant Seizures | Phase 1 | 10/03/2025 10:47 AM | Top-line results | | |
SSKN | Strata Skin Sciences Inc
| XTRAC 308nm Laser Treatment Combined with a Topical Drug in Psoriasis | — | 10/03/2025 10:50 AM | Highlights | | |
CADL | Candel Therapeutics, Inc.
| CAN-2409 Prostate cancer | — | 10/03/2025 9:05 AM | Presentation | | |
CHRS | Coherus BioSciences Inc
| CHS-114 In patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) | — | 10/03/2025 9:05 AM | Upcoming presentations | | |
ALXO | ALX Oncology Holdings Inc
| ASPEN-06 In Patients With HER2-Positive Gastric Cancer | — | 10/03/2025 9:05 AM | Updated data | | |
| | EVX-01 Metastatic Melanoma | — | 10/03/2025 9:00 AM | New Data | | |
HOWL | Werewolf Therapeutics, Inc.
| WTX-124 Solid Tumors | — | 10/03/2025 9:00 AM | Poster Presentation | | |
BCAB | BioAtla Inc
| BA3011 (Mecbotamab Vedotin) Solid Tumors | — | 10/03/2025 9:00 AM | Clinical Data | | |
XLO | Xilio Therapeutics, Inc.
| XTX301 Solid tumors | — | 10/03/2025 9:00 AM | Poster Presentation | | |
SRPT | Sarepta Therapeutics Inc
| ELEVIDYS (delandistrogene moxeparvovec-rokl) Designed to address the underlying cause of Duchenne muscular dystrophy through the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. | — | 10/03/2025 8:30 AM | Presentation | | |
ESPR | Esperion Therapeutics Inc
| NEXLETOL treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease | — | 10/03/2025 8:00 AM | Provided Update | | |
| | ALTO-101 For Schizophrenia | Fast Track Designation | 10/03/2025 7:34 AM | Designation Grant | | |
BCTBCTX | BriaCell Therapeutics Corp
| Bria-OTS In metastatic breast cancer | — | 10/03/2025 7:30 AM | Presentation | | |
OVID | Ovid Therapeutics Inc
| OV329 In Treatment-Resistant Seizures | Phase 1 | 10/03/2025 7:00 AM | Top-line results | | |
MEOBFMESO | Mesoblast Ltd
| RYONCIL For the treatment of severe and life-threatening inflammatory conditions. | — | 10/02/2025 9:04 PM | Provided Update | | |
CDTX | Cidara Therapeutics Inc
| CD388 Universal Prevention and Treatment of Influenza | — | 10/02/2025 4:01 PM | Provided Update | | |
SVRA | Savara Inc
| Molgramostim (IMPALA-2) Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | — | 10/02/2025 4:05 PM | Poster Presentation | | |
JAZZ | Jazz Pharmaceuticals PLC
| Zepzelca (lurbinectedin) Relapsed Small Cell Lung Cancer (SCLC) | — | 10/02/2025 3:35 PM | FDA approved | | |
ACAD | ACADIA Pharmaceuticals Inc
| ACP-711 GABRA3 modulators | — | 10/02/2025 9:04 AM | Late Breaking Presentation | | |
AMGN | Amgen Inc
| Repatha (Evolocumab) HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events | Phase 3 | 10/02/2025 9:00 AM | Endpoint Met | | |
| | EB-003 In treat mental health disorders | — | 10/02/2025 8:45 AM | Provided Update | | |
SSII | SS Innovations International Inc
| SSi Mantra surgical robotic system robotic surgery | — | 10/02/2025 8:30 AM | Provided Update | | |
KZIA | Kazia Therapeutics Limited
| Paxalisib Atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer | — | 10/02/2025 8:30 AM | Provided Update | | |
EWTX | Edgewise Therapeutics, Inc
| sevasemten For Becker muscular dystrophy | — | 10/02/2025 8:00 AM | Provided Update | | |
| | ECUR-506 For the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency | — | 10/02/2025 8:00 AM | Additional data | | |
SNYSNYNFRVTY | Sanofi SA Revvity Inc
| T1D 4-plex diabetic ketoacidosis (DKA) | — | 10/02/2025 8:12 AM | Provided Update | | |
HOLX | Hologic Inc
| Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. Detect Common Causes of Infectious Gastroenteritis | — | 10/02/2025 8:05 AM | FDA Clearance | | |
URGN | UroGen Pharma Ltd
| ZUSDURI for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). | — | 10/02/2025 8:00 AM | Publication | | |
TSHA | Taysha Gene Therapies Inc
| TSHA-102 Rett Syndrome | Breakthrough Therapy Designation | 10/02/2025 8:00 AM | Designation Grant | | |
ATXS | Astria Therapeutics, Inc.
| Navenibart For the Treatment of Hereditary Angioedema | Phase 3 | 10/02/2025 8:00 AM | Clinical Trial | | |
| | DNTH103 In Generalized Myasthenia Gravis (gMG) | Phase 2 | 10/02/2025 8:00 AM | Results | | |
ATHEPRNAF | Alterity Therapeutics Ltd
| ATH434-201 Investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression. | — | 10/02/2025 7:35 AM | Data | | |
AVXL | Anavex Life Sciences Corp
| ANAVEX®3-71 For the treatment of neurodegenerative and neurodevelopmental disorders | Phase 2 | 10/02/2025 7:30 AM | Top-line results | | |
| | PGN-EDODM1 For Myotonic Dystrophy Type 1 (DM1) | — | 10/02/2025 7:00 AM | Oral presentation | | |
| | PSV359 Patients with FAP-α Positive Solid Tumors | Phase 1/2a | 10/02/2025 7:00 AM | Provided Update | | |
IMRN | Immuron Ltd
| Travelan To prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC). | — | 10/02/2025 6:08 AM | Provided Update | | |
RADX | Radiopharm Theranostics
| RAD202 to treat HER2-positive advanced and metastatic cancers | — | 10/01/2025 8:00 AM | Recommendation | | |
BOLT | Bolt Biotherapeutics, Inc
| BDC-4182 patients with gastric and gastroesophageal cancer. | Phase 1 | 10/01/2025 4:05 PM | Dose escalation | | |
MBOT | Microbot Medical Inc
| LIBERTY® Endovascular Robotic Surgical System Device Study | — | 10/01/2025 9:14 AM | Provided Update | | |
CDXC | ChromaDex Corp
| Niagen Nicotinamide Riboside Chloride or NRC | — | 10/01/2025 8:32 AM | Provided Update | | |
AVHHLRCEL | AVITA Medical Inc
| RECELL System Extensive Burns and Pediatric Patients | — | 10/01/2025 8:30 AM | Provided Update | | |
ASBP | Aspire Biopharma Holdings Inc
| Sublingual Aspirin Diabetes, Weight Management | — | 10/01/2025 8:30 AM | Provided Update | | |
CRSP | CRISPR Therapeutics AG
| SyNTase Gene Editing Technology | — | 10/01/2025 8:00 AM | Presentation | | |
SLDB | Solid Biosciences Inc
| SGT-003 For Duchenne Muscular Dystrophy Gene Therapy | — | 10/01/2025 8:00 AM | Presentation | | |
CAMP | CAMP4 Therapeutics Corporation
| CMP-SYNGAP-01 Treatment rescued multiple SYNGAP1-dependent behavioral phenotypes | — | 10/01/2025 8:00 AM | Study Initiation | | |
FBIOFBIOP | Fortress Biotech Inc
| CUTX-101 Menkes disease | — | 10/01/2025 8:00 AM | Complete Response Letter | | |
MLTX | MoonLake Immunotherapeutics AG
| Sonelokimab Moderate-to-severe hidradenitis suppurativa | — | 10/01/2025 8:12 AM | Provided Update | | |
ADGM | Adagio Medical Holdings Inc
| FULCRUM-VT for Ventricular Tachycardia | — | 10/01/2025 8:00 AM | Enrollment Update | | |
ALNY | Alnylam Pharmaceuticals Inc
| Zilebesiran (ALN-AGT) Mild-to-Moderate Hypertension | Phase 3 | 10/01/2025 7:30 AM | Dosing Update | | |
KURA | Kura Oncology Inc
| KOMET-007 Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) | — | 10/01/2025 7:01 AM | Dose Update | | |
AZNAZNCF | AstraZeneca PLC
| ENHERTU® (fam-trastuzumab deruxtecan-nxki) For the treatment of adult patients with unresectable or metastatic HER2 positive | Biologics License Applications (BLA) | 10/01/2025 7:00 AM | FDA Accepted | | |
ARVN | Arvinas Inc
| ARV-102 PROTAC® degrader designed to target the LRRK2 protein | — | 10/01/2025 7:00 AM | Presentation | | |
BMYBMYMP | Bristol-Myers Squibb Company
| BMS-986446 Treatment of Alzheimer's Disease | Fast Track Designation | 10/01/2025 6:59 AM | Designation Grant | | |
| | denifanstat For Liver Diseases | Phase 1 | 10/01/2025 7:00 AM | Dose Update | | |
PHARPHGUF | Pharming Group
| Leniolisib Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) | supplemental New Drug Application (sNDA) | 10/01/2025 1:00 AM | FDA Accepted | | |